Skip to content
Portage BioTech, LLC.
Portage BioTech, LLC.Portage BioTech, LLC.
  • about us
    • overview
    • leadership
  • our portfolio
    • PORT-2 & PORT-3 – iNKT agonists
    • PORT-1 – Intratumoral Amphiphilic Formulations
    • PORT-4 – Nanolipogel Formulations
    • PORT-5 – STING Agonist with VLP Delivery
  • news
  • investors
    • overview
    • stock information
    • news releases
    • investor calendar
    • presentations & publications
    • sec filings
    • financial & regulatory reports
    • corporate governance
    • investor faqs
  • contact
  • about us
    • overview
    • leadership
  • our portfolio
    • PORT-2 & PORT-3 – iNKT agonists
    • PORT-1 – Intratumoral Amphiphilic Formulations
    • PORT-4 – Nanolipogel Formulations
    • PORT-5 – STING Agonist with VLP Delivery
  • news
  • investors
    • overview
    • stock information
    • news releases
    • investor calendar
    • presentations & publications
    • sec filings
    • financial & regulatory reports
    • corporate governance
    • investor faqs
  • contact

Daily Archives: August 30, 2021

Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year

Press ReleaseBy Portage Biotech, IncAugust 30, 2021
...

Business of Biotech: iNK T-Cell Immuno-oncology For Solid Tumors With Dr. Ian Walters

Media CoverageBy Portage Biotech, IncAugust 30, 2021
...
Copyright © All rights reserved Portage Biotech, Inc

terms of use   privacy policy   disclaimer

Go to Top